Hematologic Malignancies: From Molecular Pathology to Novel Therapeutics
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 31 August 2025 | Viewed by 67
Special Issue Editor
Interests: lymphoma; non-Hodgkin lymphoma; B cell lymphoma
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hematological malignancies comprise a heterogeneous group of diseases, in whom the knowledge of implicated pathways in pathogenesis has allowed advances in classification and targeted therapy.
In recent years, numerous genomic sequencing studies have primarily targeted recurrent mutations in individual genes, elucidating underlying oncogenic mechanisms. Moreover, molecular classifications have deepened our understanding of hematological diseases. Therefore, deeper and more detailed analyses using genomic, transcriptome, and epigenetic data have been performed by different research groups in order to refine the disease classification into clusters related to the disease impact and clinical outcomes.
This Special Issue will include reviews and research studies regarding the role of genomes, epigenetic regulation, genes implicated in cell cycle control, proliferation, apoptosis, biological processes participating in the pathogenesis, and the impact on treatment of patients.
I look forward to your submissions.
Dr. Myrna Gloria Candelaria
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pathogenesis
- B-cell lymphoma regulation
- epigenetics and hematology
- bispecific antibodies in hematology
- hematologic malignancies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
